Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
44
MIST Quote, Financials, Valuation and Earnings
Last price:
$2.08
Seasonality move
:
-24.48%
Day range:
$1.90 - $2.10
52-week range:
$0.63 - $3.06
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
8.60x
Volume:
4.7M
Avg. volume:
8.1M
1-year change:
11.89%
Market cap:
$176.3M
Revenue:
--
EPS (TTM):
-$0.86
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MIST
Milestone Pharmaceuticals, Inc.
|
-- | -$0.17 | -100% | -23.75% | $6.60 |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$67.7M | $0.16 | 25.05% | 2133.71% | $16.67 |
|
EDSA
Edesa Biotech, Inc.
|
-- | -- | -- | -- | $11.00 |
|
LEXX
Lexaria Bioscience Corp.
|
$50K | -- | 63.1% | -- | $5.33 |
|
ONCY
Oncolytics Biotech, Inc.
|
-- | -$0.05 | -- | -13.85% | $5.55 |
|
XENE
Xenon Pharmaceuticals, Inc.
|
-- | -$1.16 | -- | -43.57% | $55.40 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MIST
Milestone Pharmaceuticals, Inc.
|
$2.07 | $6.60 | $176.3M | -- | $0.00 | 0% | -- |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$16.29 | $16.67 | $2.1B | 29.03x | $0.00 | 0% | 8.65x |
|
EDSA
Edesa Biotech, Inc.
|
$1.30 | $11.00 | $9.1M | -- | $0.00 | 0% | 31.22x |
|
LEXX
Lexaria Bioscience Corp.
|
$0.56 | $5.33 | $13.9M | -- | $0.00 | 0% | 14.29x |
|
ONCY
Oncolytics Biotech, Inc.
|
$0.97 | $5.55 | $104.4M | -- | $0.00 | 0% | -- |
|
XENE
Xenon Pharmaceuticals, Inc.
|
$45.01 | $55.40 | $3.5B | -- | $0.00 | 0% | 473.02x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MIST
Milestone Pharmaceuticals, Inc.
|
73.62% | 2.776 | 33.58% | 7.85x |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
17.62% | -0.123 | 5.37% | 5.02x |
|
EDSA
Edesa Biotech, Inc.
|
-- | -0.273 | -- | 10.60x |
|
LEXX
Lexaria Bioscience Corp.
|
2.06% | -1.067 | 0.6% | 3.11x |
|
ONCY
Oncolytics Biotech, Inc.
|
87.89% | 4.153 | 0.41% | 1.61x |
|
XENE
Xenon Pharmaceuticals, Inc.
|
1.47% | 0.195 | 0.27% | 12.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MIST
Milestone Pharmaceuticals, Inc.
|
-$25K | -$11.9M | -93.03% | -858.37% | -- | -$9.8M |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$65.3M | $30.7M | 17.52% | 21.42% | 41.75% | $44.9M |
|
EDSA
Edesa Biotech, Inc.
|
-$25.9K | -$2.5M | -77.45% | -77.48% | -- | -$1.8M |
|
LEXX
Lexaria Bioscience Corp.
|
$152.6K | -$2.5M | -144.76% | -147.19% | -2155.4% | -$3.6M |
|
ONCY
Oncolytics Biotech, Inc.
|
-$67.5K | -$10M | -540.79% | -635.07% | -- | -$4.9M |
|
XENE
Xenon Pharmaceuticals, Inc.
|
-$641K | -$96.3M | -43.83% | -44.39% | -969.84% | -$72.7M |
Milestone Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns MIST or AUPH?
Aurinia Pharmaceuticals, Inc. has a net margin of -- compared to Milestone Pharmaceuticals, Inc.'s net margin of 42.95%. Milestone Pharmaceuticals, Inc.'s return on equity of -858.37% beat Aurinia Pharmaceuticals, Inc.'s return on equity of 21.42%.
Company Gross Margin Earnings Per Share Invested Capital MISTMilestone Pharmaceuticals, Inc.-- -$0.12 $77.7M AUPHAurinia Pharmaceuticals, Inc.88.87% $0.23 $444M -
What do Analysts Say About MIST or AUPH?
Milestone Pharmaceuticals, Inc. has a consensus price target of $6.60, signalling upside risk potential of 218.84%. On the other hand Aurinia Pharmaceuticals, Inc. has an analysts' consensus of $16.67 which suggests that it could grow by 2.82%. Given that Milestone Pharmaceuticals, Inc. has higher upside potential than Aurinia Pharmaceuticals, Inc., analysts believe Milestone Pharmaceuticals, Inc. is more attractive than Aurinia Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MISTMilestone Pharmaceuticals, Inc.3 1 0 AUPHAurinia Pharmaceuticals, Inc.4 3 0 -
Is MIST or AUPH More Risky?
Milestone Pharmaceuticals, Inc. has a beta of 0.408, which suggesting that the stock is 59.159% less volatile than S&P 500. In comparison Aurinia Pharmaceuticals, Inc. has a beta of 1.425, suggesting its more volatile than the S&P 500 by 42.546%.
-
Which is a Better Dividend Stock MIST or AUPH?
Milestone Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aurinia Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Milestone Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Aurinia Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MIST or AUPH?
Milestone Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Aurinia Pharmaceuticals, Inc. quarterly revenues of $73.5M. Milestone Pharmaceuticals, Inc.'s net income of -$11.9M is lower than Aurinia Pharmaceuticals, Inc.'s net income of $31.6M. Notably, Milestone Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Aurinia Pharmaceuticals, Inc.'s PE ratio is 29.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Milestone Pharmaceuticals, Inc. is -- versus 8.65x for Aurinia Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MISTMilestone Pharmaceuticals, Inc.-- -- -- -$11.9M AUPHAurinia Pharmaceuticals, Inc.8.65x 29.03x $73.5M $31.6M
-
Which has Higher Returns MIST or EDSA?
Edesa Biotech, Inc. has a net margin of -- compared to Milestone Pharmaceuticals, Inc.'s net margin of --. Milestone Pharmaceuticals, Inc.'s return on equity of -858.37% beat Edesa Biotech, Inc.'s return on equity of -77.48%.
Company Gross Margin Earnings Per Share Invested Capital MISTMilestone Pharmaceuticals, Inc.-- -$0.12 $77.7M EDSAEdesa Biotech, Inc.-- -$0.32 $12.5M -
What do Analysts Say About MIST or EDSA?
Milestone Pharmaceuticals, Inc. has a consensus price target of $6.60, signalling upside risk potential of 218.84%. On the other hand Edesa Biotech, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 746.15%. Given that Edesa Biotech, Inc. has higher upside potential than Milestone Pharmaceuticals, Inc., analysts believe Edesa Biotech, Inc. is more attractive than Milestone Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MISTMilestone Pharmaceuticals, Inc.3 1 0 EDSAEdesa Biotech, Inc.2 0 0 -
Is MIST or EDSA More Risky?
Milestone Pharmaceuticals, Inc. has a beta of 0.408, which suggesting that the stock is 59.159% less volatile than S&P 500. In comparison Edesa Biotech, Inc. has a beta of 0.078, suggesting its less volatile than the S&P 500 by 92.204%.
-
Which is a Better Dividend Stock MIST or EDSA?
Milestone Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Milestone Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Edesa Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MIST or EDSA?
Milestone Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Edesa Biotech, Inc. quarterly revenues of --. Milestone Pharmaceuticals, Inc.'s net income of -$11.9M is lower than Edesa Biotech, Inc.'s net income of -$2.2M. Notably, Milestone Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Edesa Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Milestone Pharmaceuticals, Inc. is -- versus 31.22x for Edesa Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MISTMilestone Pharmaceuticals, Inc.-- -- -- -$11.9M EDSAEdesa Biotech, Inc.31.22x -- -- -$2.2M
-
Which has Higher Returns MIST or LEXX?
Lexaria Bioscience Corp. has a net margin of -- compared to Milestone Pharmaceuticals, Inc.'s net margin of -2178.51%. Milestone Pharmaceuticals, Inc.'s return on equity of -858.37% beat Lexaria Bioscience Corp.'s return on equity of -147.19%.
Company Gross Margin Earnings Per Share Invested Capital MISTMilestone Pharmaceuticals, Inc.-- -$0.12 $77.7M LEXXLexaria Bioscience Corp.91.15% -$0.14 $5.3M -
What do Analysts Say About MIST or LEXX?
Milestone Pharmaceuticals, Inc. has a consensus price target of $6.60, signalling upside risk potential of 218.84%. On the other hand Lexaria Bioscience Corp. has an analysts' consensus of $5.33 which suggests that it could grow by 852.38%. Given that Lexaria Bioscience Corp. has higher upside potential than Milestone Pharmaceuticals, Inc., analysts believe Lexaria Bioscience Corp. is more attractive than Milestone Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MISTMilestone Pharmaceuticals, Inc.3 1 0 LEXXLexaria Bioscience Corp.1 0 0 -
Is MIST or LEXX More Risky?
Milestone Pharmaceuticals, Inc. has a beta of 0.408, which suggesting that the stock is 59.159% less volatile than S&P 500. In comparison Lexaria Bioscience Corp. has a beta of 0.628, suggesting its less volatile than the S&P 500 by 37.221%.
-
Which is a Better Dividend Stock MIST or LEXX?
Milestone Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Milestone Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Lexaria Bioscience Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MIST or LEXX?
Milestone Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Lexaria Bioscience Corp. quarterly revenues of $174K. Milestone Pharmaceuticals, Inc.'s net income of -$11.9M is lower than Lexaria Bioscience Corp.'s net income of -$2.7M. Notably, Milestone Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Lexaria Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Milestone Pharmaceuticals, Inc. is -- versus 14.29x for Lexaria Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MISTMilestone Pharmaceuticals, Inc.-- -- -- -$11.9M LEXXLexaria Bioscience Corp.14.29x -- $174K -$2.7M
-
Which has Higher Returns MIST or ONCY?
Oncolytics Biotech, Inc. has a net margin of -- compared to Milestone Pharmaceuticals, Inc.'s net margin of --. Milestone Pharmaceuticals, Inc.'s return on equity of -858.37% beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.
Company Gross Margin Earnings Per Share Invested Capital MISTMilestone Pharmaceuticals, Inc.-- -$0.12 $77.7M ONCYOncolytics Biotech, Inc.-- -$0.10 $682.8K -
What do Analysts Say About MIST or ONCY?
Milestone Pharmaceuticals, Inc. has a consensus price target of $6.60, signalling upside risk potential of 218.84%. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $5.55 which suggests that it could grow by 472.27%. Given that Oncolytics Biotech, Inc. has higher upside potential than Milestone Pharmaceuticals, Inc., analysts believe Oncolytics Biotech, Inc. is more attractive than Milestone Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MISTMilestone Pharmaceuticals, Inc.3 1 0 ONCYOncolytics Biotech, Inc.3 1 0 -
Is MIST or ONCY More Risky?
Milestone Pharmaceuticals, Inc. has a beta of 0.408, which suggesting that the stock is 59.159% less volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.880, suggesting its less volatile than the S&P 500 by 11.965%.
-
Which is a Better Dividend Stock MIST or ONCY?
Milestone Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Milestone Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MIST or ONCY?
Milestone Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Oncolytics Biotech, Inc. quarterly revenues of --. Milestone Pharmaceuticals, Inc.'s net income of -$11.9M is lower than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, Milestone Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Milestone Pharmaceuticals, Inc. is -- versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MISTMilestone Pharmaceuticals, Inc.-- -- -- -$11.9M ONCYOncolytics Biotech, Inc.-- -- -- -$10.5M
-
Which has Higher Returns MIST or XENE?
Xenon Pharmaceuticals, Inc. has a net margin of -- compared to Milestone Pharmaceuticals, Inc.'s net margin of -867.29%. Milestone Pharmaceuticals, Inc.'s return on equity of -858.37% beat Xenon Pharmaceuticals, Inc.'s return on equity of -44.39%.
Company Gross Margin Earnings Per Share Invested Capital MISTMilestone Pharmaceuticals, Inc.-- -$0.12 $77.7M XENEXenon Pharmaceuticals, Inc.-- -$1.15 $567.8M -
What do Analysts Say About MIST or XENE?
Milestone Pharmaceuticals, Inc. has a consensus price target of $6.60, signalling upside risk potential of 218.84%. On the other hand Xenon Pharmaceuticals, Inc. has an analysts' consensus of $55.40 which suggests that it could grow by 23.09%. Given that Milestone Pharmaceuticals, Inc. has higher upside potential than Xenon Pharmaceuticals, Inc., analysts believe Milestone Pharmaceuticals, Inc. is more attractive than Xenon Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MISTMilestone Pharmaceuticals, Inc.3 1 0 XENEXenon Pharmaceuticals, Inc.17 0 0 -
Is MIST or XENE More Risky?
Milestone Pharmaceuticals, Inc. has a beta of 0.408, which suggesting that the stock is 59.159% less volatile than S&P 500. In comparison Xenon Pharmaceuticals, Inc. has a beta of 1.027, suggesting its more volatile than the S&P 500 by 2.689%.
-
Which is a Better Dividend Stock MIST or XENE?
Milestone Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Milestone Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Xenon Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MIST or XENE?
Milestone Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Xenon Pharmaceuticals, Inc. quarterly revenues of --. Milestone Pharmaceuticals, Inc.'s net income of -$11.9M is higher than Xenon Pharmaceuticals, Inc.'s net income of -$90.9M. Notably, Milestone Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Xenon Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Milestone Pharmaceuticals, Inc. is -- versus 473.02x for Xenon Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MISTMilestone Pharmaceuticals, Inc.-- -- -- -$11.9M XENEXenon Pharmaceuticals, Inc.473.02x -- -- -$90.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
